Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

Journal Articles

Haemophilia A Genotype and Inhibitor Risk: Preliminary Results of a French Haemophilia Centre.

Annie Borel-Derlon, Mounia Slaoui, Jean Marc Costa, Jean Maurice Lavergne

Blood (2004) 104 (11): 3982.

https://doi.org/10.1182/blood.V104.11.3982.3982

Published: 2004

Journal Articles

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Roseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, Abdellah Benhida, Jean-Claude Bordet, Claude Negrier, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie Saint-Remy, Marc Jacquemin

Blood (2004) 103 (1): 155–157.

https://doi.org/10.1182/blood-2003-04-1321

Published: 2004

Journal Articles

Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A

Sophie Valleix, Christine Vinciguerra, Jean-Maurice Lavergne, Marco Leuer, Marc Delpech, Claude Negrier

Blood (2002) 100 (8): 3034–3036.

https://doi.org/10.1182/blood-2002-01-0277

Published: 2002

Journal Articles

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

Olivier D. Christophe, Peter J. Lenting, Ghislaine Cherel, Mariette Boon-Spijker, Jean-Maurice Lavergne, Ria Boertjes, Marie-Elisabeth Briquel, Arja de Goede-Bolder, Jenny Goudemand, Solange Gaillard, Roseline d'Oiron, Dominique Meyer, Koen Mertens

Blood (2001) 98 (5): 1416–1423.

https://doi.org/10.1182/blood.V98.5.1416

Published: 2001

Journal Articles

The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A–like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor

Anne-Sophie Ribba, Lysiane Hilbert, Jean-Maurice Lavergne, Edith Fressinaud, Catherine Boyer-Neumann, Catherine Ternisien, Irène Juhan-Vague, Jenny Goudemand, Jean-Pierre Girma, Claudine Mazurier, Dominique Meyer

Blood (2001) 97 (4): 952–959.

https://doi.org/10.1182/blood.V97.4.952

Published: 2001

Journal Articles

Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female

Rémi Favier, Jean-Maurice Lavergne, Jean-Marc Costa, Claudine Caron, Claudine Mazurier, Michèle Viémont, Marc Delpech, Sophie Valleix

Blood (2000) 96 (13): 4373–4375.

https://doi.org/10.1182/blood.V96.13.4373

Published: 2000

Journal Articles

Somatic mosaicism and compound heterozygosity in female hemophilia B

Jean-Marc Costa, Dominique Vidaud, Ingrid Laurendeau, Michel Vidaud, Edith Fressinaud, Jean-Pierre Moisan, Albert David, Dominique Meyer, Jean-Maurice Lavergne

Blood (2000) 96 (4): 1585–1587.

https://doi.org/10.1182/blood.V96.4.1585

Published: 2000

Journal Articles

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Marc Jacquemin, Renaud Lavend'homme, Abdellah Benhida, Beatrijs Vanzieleghem, Roseline d'Oiron, Jean-Maurice Lavergne, Hans H. Brackmann, Rainer Schwaab, Thierry VandenDriessche, Marinee K. L. Chuah, Marc Hoylaerts, Jean Guy G. Gilles, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie R. Saint-Remy

Blood (2000) 96 (3): 958–965.

https://doi.org/10.1182/blood.V96.3.958

Published: 2000

NARROW

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Haemophilia A Genotype and Inhibitor Risk: Preliminary Results of a French Haemophilia Centre.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A–like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor

Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female

Somatic mosaicism and compound heterozygosity in female hemophilia B

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only